Yalda Yazdani

Dr. Yalda Yazdani

Immunology Research Center, Tabriz University of Medical Sciences, Iran
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SYSaman Yasamineh
Saman Yasamineh
PYPooneh Yasamineh
Pooneh Yasamineh
HKHesam Ghafouri Kalajahi
Hesam Ghafouri Kalajahi
OGOmid Gholizadeh
Omid Gholizadeh
ZYZahra Yekanipour
Zahra Yekanipour
MDMehdi Dadashpour
Mehdi Dadashpour

15 August 2023 in Sustainability
Verified
Journal Article
Open access
PDF file
ZAZahra Amiri
Zahra Amiri
Arash HeidariArash Heidari
Arash Heidari
MDMehdi Darbandi
Mehdi Darbandi
YYYalda Yazdani
Yalda Yazdani
Nima Jafari NavimipourNima Jafari Navimipour
Nima Jafari Navimipour
MUMehmet Unal
Mehmet Unal
With the swift pace of the development of artificial intelligence (AI) in diverse spheres, the medical and healthcare fields are utilizing machine learning (ML) methodologies in numerous inventive ways. ML techniques have outstripped formerly state-of-the-art techniques in medical and healthcare practices, yielding faster and more precise outcomes. Healthcare practitioners are increasingly drawn to this technology in their initiatives relating to the Internet of Behavior (IoB). This area of research scrutinizes the rationales, approaches, and timing of human technology adoption, encompassing the domains of the Internet of Things (IoT), behavioral science, and edge analytics. The significance of ML in medical and healthcare applications based on the IoB stems from its ability to analyze and interpret copious amounts of complex data instantly, providing innovative perspectives that can enhance healthcare outcomes and boost the efficiency of IoB-based medical and healthcare procedures and thus aid in diagnoses, treatment protocols, and clinical decision making. As a result of the inadequacy of thorough inquiry into the employment of ML-based approaches in the context of using IoB for healthcare applications, we conducted a study on this subject matter, introducing a novel taxonomy that underscores the need to employ each ML method distinctively. With this objective in mind, we have classified the cutting-edge ML solutions for IoB-based healthcare challenges into five categories, which are convolutional neural networks (CNNs), recurrent neural networks (RNNs), deep neural networks (DNNs), multilayer perceptions (MLPs), and hybrid methods. In order to delve deeper, we conducted a systematic literature review (SLR) that examined critical factors, such as the primary concept, benefits, drawbacks, simulation environment, and datasets. Subsequently, we highlighted pioneering studies on ML methodologies for IoB-based medical issues. Moreover, several challenges related to the implementation of ML in healthcare and medicine have been tackled, thereby gradually fostering further research endeavors that can enhance IoB-based health and medical studies. Our findings indicated that Tensorflow was the most commonly utilized simulation setting, accounting for 24% of the proposed methodologies by researchers. Additionally, accuracy was deemed to be the most crucial parameter in the majority of the examined papers.

8 May 2023 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
AAAkram Firouzi Amandi
Akram Firouzi Amandi
EJElham Jokar
Elham Jokar
MEMajid Eslami
Majid Eslami
MDMehdi Dadashpour
Mehdi Dadashpour
MRMehdi Rezaie
Mehdi Rezaie
BNBabk Nejati
Babk Nejati

17 June 2022 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
SYSaman Yasamineh
Saman Yasamineh
HKHesam Ghafouri Kalajahi
Hesam Ghafouri Kalajahi
PYPooneh Yasamineh
Pooneh Yasamineh
OGOmid Gholizadeh
Omid Gholizadeh
HYHamed Rahmani Youshanlouei
Hamed Rahmani Youshanlouei
MDMehdi Dadashpour
Mehdi Dadashpour
The SARS-COV-2 virus has infected the world at a very high rate by causing COVID-19 disease. Nearly 507 million individuals have been infected with this virus, with approximately 1.2% of these patients being dead, indicating that this virus has been out of control in many countries. While researchers are investigating how to develop efficient drugs and vaccines versus the COVID-19 pandemic, new superseded treatments have the potential to reduce mortality. The recent application of mesenchymal stem cells (MSCs) in a subgroup of COVID-19 patients with acute respiratory distress has created potential benefits as supportive therapy for this viral contagion in patients with acute conditions and aged patients with severe pneumonia. Consequently, within this overview, we discuss the role and therapeutic potential of MSCs and the challenges ahead in using them to treat viral infections, with highlighting on COVID-19 infection. Graphical Abstract

1 November 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
BKBahman Abedi Kiasari
Bahman Abedi Kiasari
AAArash Abbasi
Arash Abbasi
NDNadia Ghasemi Darestani
Nadia Ghasemi Darestani
NANasim Adabi
Nasim Adabi
AMarsalan Moradian
arsalan Moradian
SJSheida Janati
Sheida Janati

17 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Masoud Nouri-VaskehMasoud Nouri-Vaskeh
Masoud Nouri-Vaskeh
NKNeda Khalili
Neda Khalili
ASAlireza Sadighi
Alireza Sadighi
YYYalda Yazdani
Yalda Yazdani
Ramin ZandRamin Zand
Ramin Zand
Cerebrovascular disease is the leading cause of long-term disability in the world and the third-leading cause of death in the United States. The early diagnosis of transient ischemic attack (TIA) is of great importance for reducing the mortality and morbidity of cerebrovascular diseases. Patients with TIA have a high risk of early subsequent ischemic stroke and the development of permanent nervous system lesions. The diagnosis of TIA remains a clinical diagnosis that highly relies on the patient’s medical history assessment. There is a growing list of biomarkers associated with different components of the ischemic cascade in the brain. In this review, we take a closer look at the biomarkers of TIA and their validity with a focus on the more clinically important ones using recent evidence of their reliability for practical usage.